✦ LIBER ✦

Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Scribed by N. Kroger; J.A. Perez-Simon; H. Myint; H. Klingemann; A. Shimoni; A. Nagler; R. Martino; A. Allegre; J. Tomas; R. Schwerdtfeger; M. Kiehl; A. Fauser; H.G. Sayer; A. Leon; J. Beyer; T. Zabelina; F. Ayuk; J. San Miguel; R. Brand; A. Zander

Book ID: 116277635
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 59 KB
Volume: 10
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2003.12.098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

192Dose-reduced conditioning with fludar

192Dose-reduced conditioning with fludarabine/melphalan followed by allogeneic stem cell transplantation for patients with advanced stage II/III multiple myeloma

✍ N.M. Kröger; A. Shimoni; A. Nagler; H.G. Sayer; R. Schwerdtfeger; M. Kiehl; G. W 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Fludarabine/melphalan conditioning for a

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

✍ Giralt, S; Aleman, A; Anagnostopoulos, A; Weber, D; Khouri, I; Anderlini, P; Mol 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 93 KB

Reduced-toxicity conditioning with fluda

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma

✍ Trenschel, R; Andreesen, R; Stuhler, G; Einsele, H; Kanz, L; Keilholz, U; Marine 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 147 KB

Relapse to prior autograft and chronic g

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Nicolaus Kröger; Jose A. Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Prognostic factors in allogeneic transpl

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

✍ Choon-Kee Lee; Ashraf Badros; Bart Barlogie; Christopher Morris; Maurizio Zangar 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Lenalidomide plus donor-lymphocytes infu

Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma

✍ Jean El-Cheikh; Roberto Crocchiolo; Sabine Furst; Patrick Ladaique; Luca Castagn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 338 KB